Status:
UNKNOWN
Effect of Unani Medicine for the Management of Anomalies Associated With Polycystic Ovarian Syndrome
Lead Sponsor:
Hamdard University
Conditions:
Comparative Study
Eligibility:
FEMALE
18-38 years
Phase:
PHASE1
Brief Summary
Currently available medications for PCOS are symptom(s) oriented but have limitations because of its complex pathophysiology. The most preferred drug against PCOS is metformin which act as an insulin ...
Detailed Description
Polycystic ovarian syndrome (PCOS) is a common endocrine disorder in reproductive age women, with a prevalence between 5%-15%. Currently, sedentary lifestyle, excessive intake of junk food and increas...
Eligibility Criteria
Inclusion
- Inclusion criteria No complications record of reproductive system, 4) PCOS diagnosed using Rotterdam criteria fulfilling any two of the following: (i) Menstrual irregularity or oligo-/anovulation, (ii) Hyperandrogenism (clinically and/or biochemically), (iii) Polycystic appearance on ultrasound
- Exclusion criteria
- 1\) Patients with severe adverse drug reactions, 2) Record of cardiovascular, diabetes, hepatic and neoplastic disorders or other concurrent medical illnesses, 3) Hormonal contraceptive used within 6 months, or anti-obesity drugs within 3 months of the study, 4) Irregular menstrual bleeding other than PCOS and 5) Positive pregnancy test.
Exclusion
Key Trial Info
Start Date :
October 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06199544
Start Date
October 1 2022
End Date
December 1 2024
Last Update
January 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shifa ul mulk memorial hospital
Karachi, Sindh, Pakistan